P4616 - Relationship Between the Level of Hepatic Steatosis and Body Mass Index in Patients of the Centro de Gastroenterología Avanzada in the Period January 2021-August 2022

Pablo J. Socias-Pappaterra, MD¹, Fernando Contreras, MD¹, Eduardo Garcia-Gobaira, MD¹, Yousef S. Ebrahim Ibrahim, MD¹, Vivian Ho Sang, MD¹, Michelle Luis, MD¹, Isabella Mella, MD², Ronaldo Pichardo-Gonzalez, MD¹, Diego Abreu, MD³, Cesar Ortiz, MD^3
1Centro de Gastroenterologia Avanzada, Santo Domingo, Distrito Nacional, Dominican Republic; ²cga, Santo Domingo, Distrito Nacional, Dominican Republic; ³CGA, Santo Domingo, Distrito Nacional, Dominican Republic

Introduction: Steatotic liver disease (SLD) is the most common chronic liver condition, affecting around 25% of the world's population. Its incidence is concerningly increasing every year, as well as the prevalence of obesity, the greatest risk factor of SLD. Fibroscan or transient elastography functions as a non-invasive diagnostic tool to evaluate steatosis and fibrosis in patients with liver conditions, by using a controlled attenuation parameter (CAP). The objective of this study is to determine the correlation between CAP-measured steatosis and Body Mass Index (BMI).

Methods: A retrospective study which included 173 patients who underwent Fibroscan between January 2021 and August 2022 was conducted. Their electronic medical records were examined and data was collected. BMI, CAP, age, sex, and sociodemographic variables were among those selected. Frequency analysis and Spearman correlation with a 95% confidence interval were obtained with the JASP software.

Results: A total sample of 173 patients was gathered, which included 112 (64.7%) men and a mean age range of 56-65 years (29.5%), who were evaluated using Fibroscan. Spearman’s correlation demonstrated a positive and statistically significant association between the different classes of BMI and SLD. 41.04% of the patients were categorized as overweight, while 25.43% had class 1 obesity. This evidence shows a similar trend when being compared with the Dominican population, which revealed that in 2021, 36.5% were overweight, and 33.6% had obesity. In respect to SLD severity, 34.1% and 32.4% were classified as grade 0 and grade 3, respectively. Furthermore, 83.8% had fibrosis stage F0-F1. This center’s results resemble the similarities obtained from the Dominican population and support Fibroscan as an efficient diagnostic tool for SLD.

Discussion: These results display a positive and statistically significant correlation between hepatic steatosis and BMI. The different levels of BMI measured in our study correlate with the Dominican Republic’s general population, and notably, most patients were in Fibrosis stage F0-F1, demonstrating that opportune intervention is possible. For these reasons, early detection of SLD through the use of Fibroscan is necessary, and healthcare professionals should perceive risk factors, such as obesity, to prevent its progression. Overall, to intensify Fibroscan’s accuracy, a combination with other non-invasive tools, such as the fatty liver index, is necessary.


Disclosures:


Pablo J. Socias-Pappaterra, MD¹, Fernando Contreras, MD¹, Eduardo Garcia-Gobaira, MD¹, Yousef S. Ebrahim Ibrahim, MD¹, Vivian Ho Sang, MD¹, Michelle Luis, MD¹, Isabella Mella, MD², Ronaldo Pichardo-Gonzalez, MD¹, Diego Abreu, MD³, Cesar Ortiz, MD³. P4616 - Relationship Between the Level of Hepatic Steatosis and Body Mass Index in Patients of the Centro de Gastroenterología Avanzada in the Period January 2021-August 2022, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.